Article shared by HWGB BioTech - www.hwgbbiotech.com - Frontiers published HWGB’s JV partner EBI retrospective study demonstrating the role poliovirus vaccination may have in providing antibodies against SARS-CoV-2 infection

 E-Mo Biology, Inc. is pleased to announce our retrospective serological study demonstrating the role poliovirus vaccination may have in providing antibodies against SARS-CoV-2 infection has been accepted for publication in the Frontiers in Medicine Journal, in the Infectious Diseases Surveillance, Prevention, and Treatment issue. The manuscript is entitled, “Poliovirus Vaccination Induces a Humoral Immune Response that Cross Reacts with SARS-CoV-2.”

 
The publication presents a novel concept that the poliovirus vaccine can induce an adaptive humoral immune response. Antibodies created by poliovirus vaccination bind the RNA-dependent RNA polymerase (RdRp) protein of both poliovirus and SARSCoV-2, thereby preventing SARS-CoV-2 infection. In vitro laboratory data demonstrated sera from individuals that have recently been inoculated with the poliovirus vaccine have the ability to inhibit viral replication that would cause an individual to become ill. Data also showed adults that have recently received the poliovirus vaccine may have a similar degree of protection from SARS-CoV-2 as children that have received the poliovirus vaccine as part of their childhood vaccinations.
 
E-Mo Biology, Inc. believes these findings represent a new milestone and demonstrate the potential that the poliovirus vaccine may have in ameliorating the impact that COVID-19 may have on individuals across the world. For more information, the original, peer-reviewed research article can be accessed at: doi: 10.3389/fmed.2021.710010 Brittany A. Comunale, MPH, MBA, CCRC, PMP Chief Operating Officer, E-Mo Biology, Inc.

Comments

Popular posts from this blog

Article shared by HWGB BioTech - www.hwgbbiotech.com - Poliovirus Vaccination Induces a Humoral Immune Response that Cross Reacts with SARS-CoV-2

Article shared by HWGB BioTech - www.hwgbbiotech.com - D’VIRIA IS THE FIRST MOH APPROVED CHLORINE DIOXIDE SURFACE DISINFECTANT IN MALAYSIA